Financial Performance - For the three months ended June 30, 2025, the company reported a net income of $13.7 million, an increase of $3.0 million or 28.0% compared to the same period in 2024 [18] - Adjusted net income for the same period was $14.5 million, up $2.1 million or 16.9% year-over-year [19] - Voyage revenues increased to $38.6 million, a rise of $1.0 million or 2.7% from the previous year [20] Operational Metrics - The company achieved a fleet utilization rate of 99.4% for the three months ended June 30, 2025, compared to 100% in the same period of 2024 [21] - Average daily hire gross of commissions was approximately $70,730 per day per vessel, down from $72,010 in the prior year [21] - The company maintained a strong contract backlog estimated at approximately $0.9 billion with an average remaining contract duration of 5.4 years [11][32] Cash Flow and Liquidity - The company generated net cash from operating activities of $24.3 million for the three months ended June 30, 2025, an increase of $1.8 million or 8.0% from the same period in 2024 [28] - As of June 30, 2025, the cash balance stood at $77.9 million, with no debt maturities until mid-2029 [14][13] - The company redeemed all 2,200,000 Series B Preferred Units for a total payment of $56.0 million, funded by internal cash reserves [30] Debt and Financing - The company reported total outstanding debt of $300.8 million, with annual debt amortization of $44.2 million, representing 14.6% of total debt [13] - Net interest and finance costs decreased to $5.2 million for the three months ended June 30, 2025, down 36.6% from $8.2 million in the same period of 2024 [24] Market Environment - The company remains insulated from short-term volatility in the LNG market due to its contracts-based business model [10] - Current U.S. and E.U. sanctions related to the Russian conflict do not materially affect the company's operations or financial condition [16]

Spain site opens with two R/R AML subjects enrolled; One treated On track to recruit 45 subjects in 4Q25 for initial data unblinding HOUSTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced that it has enrolled the first two subjects, and treated one, in the European Union (EU) in its pivotal Phase 2B/3, ...

Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter Company seeks alignment on reasonable path forward for Zynquista NDA resubmission FDA feedback from Type D meeting expected by end of September THE WOODLANDS, Texas, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the Company has submitted additional clinical data to the U.S. Food and Drug Adminis ...

VANCOUVER, British Columbia, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath testing devices is pleased to report its participation in the NSC Safety Congress & Expo, taking place September 15–17, 2025 in Denver, Colorado. The NSC Safety Congress & Expo is the world’s largest annual event dedicated to workplace safety, health, and environmental professionals and will have thousan ...

NEW PORT RICHEY, Fla., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Zeo Energy Corp. (Nasdaq: ZEO) (“Zeo,” “Zeo Energy,” or the “Company”), a Florida-based provider of residential solar and commercial long-duration energy-storage solutions, today announced that the Company will be presenting at ROTH Capital’s 12th Annual Solar & Storage Symposium on Tuesday, September 9, at the upcoming RE+ trade show in Las Vegas, Nevada, which runs from September 8-11, 2025. The symposium, hosted by ROTH Capital during RE+, provide ...

Core Viewpoint - Lifeward Ltd. has received CE mark approval for the ReWalk 7 Personal Exoskeleton, allowing for its commercial sale in the European Union, which is expected to drive revenue growth and market adoption in Europe [1][2]. Company Overview - Lifeward is a global leader in innovative medical technology aimed at transforming the lives of individuals with physical limitations or disabilities, with a mission to drive innovation in rehabilitation and recovery [3]. - The company has a diverse portfolio that includes the ReWalk Exoskeleton, AlterG Anti-Gravity System, ReStore Exo-Suit, and MyoCycle FES System, and operates in the United States, Israel, and Germany [3]. Product Details - The ReWalk 7 features advancements such as cloud connectivity, push-button control, customizable walking speeds, and seamless activation for stairs and curbs, enhancing user experience for individuals with spinal cord injuries [2]. - The European market, particularly Germany, is significant for Lifeward, representing approximately 40% of its exoskeleton sales, with established reimbursement processes for personal exoskeletons [1][2]. Market Position - Lifeward GmbH serves as the primary sales force in Europe, with Germany being the second largest market for ReWalk personal exoskeletons globally [2]. - The company has established supply contracts with major insurance carriers in Germany, facilitating reimbursement for about 45% of individuals with statutory health insurance coverage [2].

BERKELEY HEIGHTS, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it has made a $5 million strategic minority equity investment in Talphera, Inc. (Nasdaq: TLPH), acquiring 9,090,909 shares at an at-market price of $0.55 per share as part of Talphera’s concurrently announced private placement financing. Talphera expec ...

Kennewick, WA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) announced new data demonstrating the exceptional precision of its proprietary Precision Radionuclide Therapy (RadioGel® for human therapies and IsoPet® for veterinary applications) Advancing Targeted Cancer Therapies The therapeutic ratio is the amount of radiation delivered to a tumor compared to surrounding healthy tissue and is a critical measure of treatment precision. A high therapeutic ratio minimizes collateral damage while ma ...

BELVIDERE, NJ, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), locally grown, organic, and sustainable produce and products, today announced it will showcase its innovative, award-winning Kick. Sports Nutrition line, recently recognized as the 2025 Sports Nutrition Product of the Year by the Mindful Awards, at ECRM’s Vitamin, Weight Management & Sports Nutrition Session, taking p ...

Establishes the official Dogecoin Treasury of the Dogecoin Foundation and its Newly Established Corporate Arm, the House of Doge The transaction consisted of marquee institutional and crypto native investors including, but not limited to, MOZAYYX, Pantera, GSR, FalconX and Borderless OMAHA, Neb., Sept. 08, 2025 (GLOBE NEWSWIRE) -- CleanCore Solutions, Inc. (NYSE American: ZONE) (“CleanCore” or the “Company”), today announced the closing of its private investment in public equity (PIPE) financing. The offeri ...